[Specificities of diabetes in acute coronary syndromes]

Rev Med Suisse. 2011 Jun 1;7(297):1200-2, 1204-6.
[Article in French]

Abstract

Contrary to the decline in the prevalence of several risk factors such as hypertension, hypercholesterolemia and smoking, diabetes is an expanding health burden in the western world. Because of the proatherosclerotic, proinflammatory, and prothrombotic states associated with diabetes, diabetic patients with acute coronary syndromes (ACS) are at high risk of subsequent cardiovascular events. However, they derive greater benefit from aggressive platelet inhibition and an early invasive strategy than non-diabetic individuals. Despite the documented efficacy, diabetic patients with ACS receive evidence-based treatments less frequently than non-diabetic individuals.

MeSH terms

  • Acute Coronary Syndrome / complications*
  • Acute Coronary Syndrome / drug therapy*
  • Acute Coronary Syndrome / physiopathology
  • Acute Coronary Syndrome / therapy
  • Algorithms
  • Angioplasty
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Clopidogrel
  • Diabetes Complications / drug therapy*
  • Diabetes Complications / physiopathology
  • Diabetes Complications / therapy
  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus / physiopathology
  • Diabetes Mellitus / therapy
  • Drug Therapy, Combination
  • Enoxaparin / therapeutic use
  • Evidence-Based Medicine
  • Fibrinolytic Agents / therapeutic use
  • Heparin / therapeutic use
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Piperazines / therapeutic use
  • Platelet Aggregation Inhibitors / therapeutic use
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
  • Prasugrel Hydrochloride
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Secondary Prevention / methods
  • Stents
  • Thiophenes / therapeutic use
  • Ticlopidine / analogs & derivatives
  • Ticlopidine / therapeutic use
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Enoxaparin
  • Fibrinolytic Agents
  • Hypoglycemic Agents
  • Piperazines
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Thiophenes
  • Heparin
  • Clopidogrel
  • Prasugrel Hydrochloride
  • Ticlopidine